[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332322-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332322-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","patients-with-cancer-who-will-be-cured-and-projections-of-complete-prevalence-in-italy-from-2018-to-2030","Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030","","Cancer survivor counts and future healthcare demand require credible estimates, yet cure prevalence—patients who will not die from cancer by time since diagnosis—has been insufficiently quantified. Using Italian cancer registry data spanning 9 to 40 years, the study computes limited-duration prevalence, complete prevalence for 2018, projections through 2030, and cure prevalence by cancer type, sex, age, and time since diagnosis. Results report 3,347,809 patients alive in 2018, rising to 4,012,376 by 2030.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/patients-with-cancer-who-will-be-cured-and-projections-of-complete-prevalence-in-italy-from-2018-to-2030/332322/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/patients-with-cancer-who-will-be-cured-and-projections-of-complete-prevalence-in-italy-from-2018-to-2030/332322.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What gap in knowledge does the study address?","Question",{"text":63,"@type":64},"It addresses the lack of data on cure prevalence, defined as the percentage of patients who will not die of cancer by time since diagnosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What data and approach are used to produce the projections?",{"text":68,"@type":64},"The study uses Italian cancer registry data (9–40 years, median 22) covering 47% of the population to calculate prevalence measures and projections to 2030 by key demographics and time since diagnosis.",{"name":70,"@type":61,"acceptedAnswer":71},"What do the results report for Italy in 2018 and 2030?",{"text":72,"@type":64},"In 2018, 3,347,809 people were alive after a cancer diagnosis (5.6% of the resident population), projected to increase to 4,012,376 by 2030 (6.9%).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332322,1790471757,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ORIGINAL RESEARCH  \nPatients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030  \nS. Guzzinati1􀀁, F. Toffolutti2, S. Francisci3, A. De Paoli1, F. Giudici2, R. De Angelis4, E. Demuru4, L. Botta5, A. Tavilla3,  \nG. Gatta5, R. Capocaccia6, M. Zorzi1, A. Caldarella7, E. Bidoli2, F. Falcini8, R. Bruni9, E. Migliore10, A. Puppo11, M. Ferrante12, C. Gasparotti13, M. L. Gambino14, G. Carrozzi15, F. Bianconi16, A. Musolino17, R. Cavallo18, W. Mazzucco19, M. Fusco20,  \nP. Ballotari21, G. Sampietro22, S. Ferretti23 , 24, L. Mangone25, W. Mantovani26, M. Mian27 , 28, G. Cascone29, F. Manzoni30,  \nR. Galasso31, D. Piras32, M. T. Pesce33, F. Bella34, P. Seghini35, A. C. Fanetti36, P. Pinna37, D. Serraino2, S. Rossi4 &  \nL. Dal Maso2 􀀁 , AIRTUM Working Groupy  \n1Veneto Tumour Registry, Epidemiological Department, Azienda Zero, Padova; 2Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano; 3National Centre for Disease Prevention and Health Promotion, National Institute of Health, Rome; 4Department of Oncology and Molecular Medicine, National Institute of Health, Rome; 5Evaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 6Epidemiologia & Prevenzione Editorial Board, Milan; 7Tuscany Cancer Registry, Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence; 8Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)“Dino Amadori”, Meldola, Forlì; 9Coordination Centre of the Cancer Registry of Puglia-Strategic Regional Agency for Health and Social Care (AReSS), Bari; 10Piedmont Cancer Registry, CPO Piemonte and University of Turin, Turin; 11Liguria Cancer Registry, IRCCS Ospedale Policlinico San Martino, Genova; 12Registro Tumori Integrato di Catania-Messina-Enna, UOC Igiene Ospedaliera, Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco, Catania; 13ATS Brescia Cancer Registry, Struttura Semplice di Epidemiologia, Brescia; 14Registro Tumori ATS Insubria (Provincia di Como e Varese) Responsabile S.S. Epidemiologia Registri Specializzati e Reti di Patologia, Varese; 15EmiliaRomagna Cancer Registry, Modena Unit, Public Health Department, Local Health Authority, Modena; 16Umbria Cancer Registry, PuntoZero Scarl, Perugia; 17EmiliaRomagna Cancer Registry, Parma Unit, Medical Oncology Unit, University Hospital of Parma, Parma; 18Registro Tumori ASL Salerno-Dipartimento di Prevenzione, Salerno; 19Clinical epidemiology and Cancer Registry Unit, Azienda Ospedaliera Universitaria Policlinico (AOUP) di Palermo, Palermo; 20UOSD Registro Tumori ASL Napoli 3 Sud, Napoli; 21SC Osservatorio Epidemiologico, ATS Val Padana, Mantova; 22Bergamo Cancer Registry, Epidemiological Service, Agenzia di Tutela della Salute, Bergamo; 23Emilia-Romagna Cancer Registry, Ferrara Unit, Local Health Authority, Ferrara; 24University of Ferrara, Ferrara; 25Emilia-Romagna Cancer Registry, Reggio Emilia Unit, Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia; 26Trento Province Cancer Registry, Clinical and Evaluative Epidemiology Unit, Local Health Authority, Trento; 27Innovation, Research and Teaching Service (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU) Bolzano-Bozen; 28College of Health Care-Professions Claudiana, Bolzano-Bozen; 29Azienda Sanitaria Provinciale Ragusa - UOSD Registro Tumori, Ragusa; 30Cancer Registry of the Province of Pavia e Epidemiology Unit e Health Protection Agency of Pavia, Pavia; 31Unit of Regional Cancer Registry, Clinical Epidemiology and Biostatistics, IRCCS CROB, Rionero in Vulture (PZ); 32Nord Sardegna Cancer Registry, ASL Sassari, Sassari; 33Monitoraggio rischio ambientale e Registro Tumori ASL Caserta, Caserta; 34Siracusa Cancer Registry, Provincial Health Authority of Siracusa, Siracusa; 35Emilia-Romagna C","cbCaiv8l30xt9pGe","https://ap.wps.com/l/cbCaiv8l30xt9pGe","pdf",430162,"English","# Background\n# Materials and methods\n# Results","[{\"question\":\"What gap in knowledge does the study address?\",\"answer\":\"It addresses the lack of data on cure prevalence, defined as the percentage of patients who will not die of cancer by time since diagnosis.\"},{\"question\":\"What data and approach are used to produce the projections?\",\"answer\":\"The study uses Italian cancer registry data (9–40 years, median 22) covering 47% of the population to calculate prevalence measures and projections to 2030 by key demographics and time since diagnosis.\"},{\"question\":\"What do the results report for Italy in 2018 and 2030?\",\"answer\":\"In 2018, 3,347,809 people were alive after a cancer diagnosis (5.6% of the resident population), projected to increase to 4,012,376 by 2030 (6.9%).\"}]","Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030 | PDF",1789997710]